Charles River Laboratories International, Inc. $CRL Holdings Raised by UMB Bank n.a.

UMB Bank n.a. increased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 290.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 688 shares of the medical research company’s stock after purchasing an additional 512 shares during the quarter. UMB Bank n.a.’s holdings in Charles River Laboratories International were worth $104,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. boosted its holdings in shares of Charles River Laboratories International by 407.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 997,488 shares of the medical research company’s stock valued at $150,142,000 after buying an additional 800,762 shares during the period. Assenagon Asset Management S.A. lifted its holdings in Charles River Laboratories International by 1,721.1% in the first quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company’s stock worth $85,811,000 after acquiring an additional 538,792 shares during the last quarter. Royal Bank of Canada boosted its stake in Charles River Laboratories International by 304.7% in the first quarter. Royal Bank of Canada now owns 627,710 shares of the medical research company’s stock valued at $94,484,000 after acquiring an additional 472,606 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of Charles River Laboratories International by 144.3% during the first quarter. Ameriprise Financial Inc. now owns 544,825 shares of the medical research company’s stock valued at $82,007,000 after purchasing an additional 321,789 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Charles River Laboratories International by 16,153.2% during the 1st quarter. SG Americas Securities LLC now owns 267,202 shares of the medical research company’s stock worth $40,219,000 after purchasing an additional 265,558 shares during the period. Institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the subject of a number of analyst reports. Evercore ISI boosted their price objective on Charles River Laboratories International from $180.00 to $190.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Jefferies Financial Group raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and boosted their price target for the company from $142.00 to $195.00 in a report on Tuesday, September 9th. Barclays increased their price objective on shares of Charles River Laboratories International from $155.00 to $165.00 and gave the stock an “equal weight” rating in a report on Thursday, August 7th. Citigroup raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and boosted their target price for the company from $150.00 to $200.00 in a research note on Wednesday, July 9th. Finally, JPMorgan Chase & Co. raised their price target on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Six equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $177.07.

Charles River Laboratories International Trading Down 0.7%

Charles River Laboratories International stock opened at $149.23 on Thursday. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $230.02. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. The stock has a market capitalization of $7.34 billion, a PE ratio of -112.20, a price-to-earnings-growth ratio of 4.02 and a beta of 1.47. The firm has a 50 day simple moving average of $159.99 and a 200-day simple moving average of $148.04.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.62. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The firm’s revenue for the quarter was up .6% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.80 earnings per share. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $157.60, for a total value of $126,080.00. Following the sale, the executive vice president directly owned 24,116 shares in the company, valued at approximately $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).